Do COVID-19 Antibodies Provide Long-Term Protection?

Area of Science:

• Immunology
• Virology
• Infectious Diseases

Background:

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection elicits an immune response characterized by immunoglobulin G (IgG) and IgM antibodies.
• Antibody dynamics, specifically the duration of detectable IgG and IgM, require further investigation to understand long-term immunity.

Purpose of the Study:

• To assess the persistence of humoral immunity against SARS-CoV-2 in individuals following mild infection.
• To compare antibody longevity in symptomatic versus asymptomatic COVID-19 cases.

Main Methods:

• Serum samples were collected from 728 participants at a tertiary care hospital in Pakistan.
• Antibody testing was performed at baseline, with follow-up testing after 60 days for seropositive individuals.
• Enzyme-linked immunosorbent assay (ELISA) was used for SARS-CoV-2 antibody detection.

Main Results:

• 10.8% of participants were seropositive at baseline.
• After 60 days, 37 participants remained seropositive.
• A higher percentage of asymptomatic individuals (54.0%) seroconverted to negative compared to symptomatic individuals (42.8%) over the 60-day period.

Conclusions:

• Humoral immunity against SARS-CoV-2 is not durable in individuals with mild symptoms.
• Antibody persistence varies between symptomatic and asymptomatic cases.
• Long-term protection conferred by SARS-CoV-2 antibodies should be carefully considered, necessitating further large-scale research.